Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1990 12
1991 4
1992 13
1993 7
1994 5
1995 12
1996 9
1997 8
1998 18
1999 23
2000 13
2001 31
2002 40
2003 31
2004 31
2005 47
2006 54
2007 40
2008 54
2009 38
2010 49
2011 49
2012 51
2013 48
2014 47
2015 40
2016 32
2017 36
2018 45
2019 30
2020 31
2021 33
2022 19
2023 14
2024 17
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

946 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.
O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. O'Byrne PM, et al. N Engl J Med. 2018 May 17;378(20):1865-1876. doi: 10.1056/NEJMoa1715274. N Engl J Med. 2018. PMID: 29768149 Free article. Clinical Trial.
Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group), twice-daily placebo plus budesonide-formoterol (200 mug of budesonide and 6 mug of formoterol) used as needed (budesonide-f …
Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group), …
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Ferguson GT, et al. Lancet Respir Med. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16. Lancet Respir Med. 2018. PMID: 30232048 Clinical Trial.
We randomly assigned patients (2:2:1:1) using an interactive web response system to receive budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler 320/18/9.6 mug (BGF MDI), glycopyrrolate/ formoterol fumarate metered-dose inhaler 18/9.6 mug …
We randomly assigned patients (2:2:1:1) using an interactive web response system to receive budesonide/glycopyrrolate/formoterol f …
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, Rossman K, St Rose E, Trivedi R, Ballal S, Darken P, Aurivillius M, Reisner C, Dorinsky P. Martinez FJ, et al. Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC. Am J Respir Crit Care Med. 2021. PMID: 33252985 Free PMC article. Clinical Trial.
Rationale: In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) significantly …
Rationale: In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive …
As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.
Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. Bateman ED, et al. N Engl J Med. 2018 May 17;378(20):1877-1887. doi: 10.1056/NEJMoa1715275. N Engl J Med. 2018. PMID: 29768147 Free article. Clinical Trial.
Patients were randomly assigned to receive twice-daily placebo plus budesonide-formoterol (200 mug of budesonide and 6 mug of formoterol) used as needed or budesonide maintenance therapy with twice-daily budesonide (200 mug) plus terbutaline (0.5 mg) used as needed. …
Patients were randomly assigned to receive twice-daily placebo plus budesonide-formoterol (200 mug of budesonide and 6 mug of form …
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID, Williams M, Weatherall M; Novel START Study Team. Beasley R, et al. N Engl J Med. 2019 May 23;380(21):2020-2030. doi: 10.1056/NEJMoa1901963. Epub 2019 May 19. N Engl J Med. 2019. PMID: 31112386 Clinical Trial.
Patients were randomly assigned to one of three treatment groups: albuterol (100 mug, two inhalations from a pressurized metered-dose inhaler as needed for asthma symptoms) (albuterol group); budesonide (200 mug, one inhalation through a Turbuhaler twice daily) plus as-needed alb …
Patients were randomly assigned to one of three treatment groups: albuterol (100 mug, two inhalations from a pressurized metered-dose inhale …
Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis.
Beasley R, Harrison T, Peterson S, Gustafson P, Hamblin A, Bengtsson T, Fagerås M. Beasley R, et al. JAMA Netw Open. 2022 Mar 1;5(3):e220615. doi: 10.1001/jamanetworkopen.2022.0615. JAMA Netw Open. 2022. PMID: 35230437 Free PMC article.
IMPORTANCE: The Global Initiative for Asthma (GINA) recommends 2 alternative treatments for patients receiving treatment at steps 3 to 5: single inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) or inhaled corticosteroid-long-ac …
IMPORTANCE: The Global Initiative for Asthma (GINA) recommends 2 alternative treatments for patients receiving treatment at steps 3 to 5: si …
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD.
Muiser S, Imkamp K, Seigers D, Halbersma NJ, Vonk JM, Luijk BHD, Braunstahl GJ, van den Berg JW, Kroesen BJ, Kocks JWH, Heijink IH, Reddel HK, Kerstjens HAM, van den Berge M. Muiser S, et al. Thorax. 2023 May;78(5):451-458. doi: 10.1136/thorax-2022-219620. Epub 2023 Feb 1. Thorax. 2023. PMID: 36725331 Clinical Trial.
BACKGROUND: Maintenance and reliever therapy (MART) with inhaled corticosteroid (ICS)/formoterol effectively reduces exacerbations in asthma. We aimed to investigate its efficacy compared with fixed-dose fluticasone/salmeterol in chronic obstructive pulmonary disease (COPD …
BACKGROUND: Maintenance and reliever therapy (MART) with inhaled corticosteroid (ICS)/formoterol effectively reduces exacerbations in …
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, Mane S, Vohlidkova A, Martindale J, Williams M, Shirtcliffe P, Holliday M, Weatherall M, Beasley R; PRACTICAL study team. Hardy J, et al. Lancet. 2019 Sep 14;394(10202):919-928. doi: 10.1016/S0140-6736(19)31948-8. Epub 2019 Aug 23. Lancet. 2019. PMID: 31451207 Clinical Trial.
We investigated the efficacy of combination budesonide-formoterol reliever therapy compared with maintenance budesonide plus as-needed terbutaline. ...The findings support the 2019 Global Initiative for Asthma recommendation that inhaled corticosteroid-formoterol re …
We investigated the efficacy of combination budesonide-formoterol reliever therapy compared with maintenance budesonide plus as-neede …
Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Bourdin A, Molinari N, Ferguson GT, Singh B, Siddiqui MK, Holmgren U, Ouwens M, Jenkins M, De Nigris E. Bourdin A, et al. Adv Ther. 2021 Jun;38(6):3089-3112. doi: 10.1007/s12325-021-01703-z. Epub 2021 Apr 30. Adv Ther. 2021. PMID: 33929661 Free PMC article.
A previous network meta-analysis showed comparable efficacy of the ICS/LAMA/LABA, budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR) 320/18/9.6 g, to other fixed-dose and open combination triple therapies at 24 weeks in COPD. ...Across all outcomes …
A previous network meta-analysis showed comparable efficacy of the ICS/LAMA/LABA, budesonide/glycopyrronium bromide/formoterol fum …
Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough variant asthma.
Yi F, Zhan C, Liu B, Li H, Zhou J, Tang J, Peng W, Luo W, Chen Q, Lai K. Yi F, et al. Respir Res. 2022 Oct 10;23(1):279. doi: 10.1186/s12931-022-02114-6. Respir Res. 2022. PMID: 36217131 Free PMC article. Clinical Trial.
This study aimed to investigate and compare the efficacy of montelukast alone, budesonide/formoterol alone and the combination of both in the treatment of CVA. METHODS: Ninety-nine CVA patients were assigned randomly in a 1:1:1 ratio to receive montelukast (M group: 10 mg, …
This study aimed to investigate and compare the efficacy of montelukast alone, budesonide/formoterol alone and the combination of bot …
946 results